Royalty Pharma (RPRX) Competitors

$50.44 +0.24 (+0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$50.46 +0.02 (+0.04%)

As of 07:47 PM Eastern

RPRX vs. ZTS, JAZZ, CORT, NKTR, and SUPN

Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Zoetis (ZTS), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.

How does Royalty Pharma compare to Zoetis?

Zoetis (NYSE:ZTS) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

: Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zoetis $9.47B 5.00 $2.67B $6.02 18.70
Royalty Pharma $2.38B 12.24 $770.95M $1.35 37.36
: Zoetis presently has a consensus price target of $151.75, indicating a potential upside of 34.78%. Royalty Pharma has a consensus price target of $50.33, indicating a potential downside of 0.21%. Given Zoetis' higher possible upside, equities research analysts clearly believe Zoetis is more favorable than Royalty Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoetis
1 Sell rating(s)
7 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.40
Royalty Pharma
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 1.9%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.9%. Zoetis pays out 35.2% of its earnings in the form of a dividend. Royalty Pharma pays out 69.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years and Royalty Pharma has raised its dividend for 5 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
: In the previous week, Zoetis had 20 more articles in the media than Royalty Pharma. MarketBeat recorded 32 mentions for Zoetis and 12 mentions for Royalty Pharma. Zoetis' average media sentiment score of 1.12 beat Royalty Pharma's score of 1.07 indicating that Zoetis is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zoetis
24 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive
Royalty Pharma
8 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Zoetis has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
: Royalty Pharma has a net margin of 32.38% compared to Zoetis' net margin of 28.24%. Zoetis' return on equity of 62.02% beat Royalty Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Zoetis 28.24% 62.02% 19.24%
Royalty Pharma 32.38% 28.21% 14.55%
: 92.8% of Zoetis shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	5.00	$2.67B	$6.02	18.70
Royalty Pharma	$2.38B	12.24	$770.95M	$1.35	37.36

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	24 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Royalty Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	28.24%	62.02%	19.24%
Royalty Pharma	32.38%	28.21%	14.55%

Summary

Zoetis beats Royalty Pharma on 14 of the 19 factors compared between the two stocks.

How does Royalty Pharma compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

: Jazz Pharmaceuticals currently has a consensus price target of $216.87, indicating a potential upside of 2.17%. Royalty Pharma has a consensus price target of $50.33, indicating a potential downside of 0.21%. Given Jazz Pharmaceuticals' higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)

14 Buy rating(s)

1 Strong Buy rating(s)
2.83
Royalty Pharma
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Jazz Pharmaceuticals has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
: Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jazz Pharmaceuticals $4.27B 3.12 -$356.15M -$5.97 N/A
Royalty Pharma $2.38B 12.24 $770.95M $1.35 37.36
: Royalty Pharma has a net margin of 32.38% compared to Jazz Pharmaceuticals' net margin of -8.35%. Royalty Pharma's return on equity of 28.21% beat Jazz Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals -8.35% 6.87% 2.44%
Royalty Pharma 32.38% 28.21% 14.55%
: In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Royalty Pharma. MarketBeat recorded 14 mentions for Jazz Pharmaceuticals and 12 mentions for Royalty Pharma. Jazz Pharmaceuticals' average media sentiment score of 1.11 beat Royalty Pharma's score of 1.07 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
7 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Royalty Pharma
8 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.12	-$356.15M	-$5.97	N/A
Royalty Pharma	$2.38B	12.24	$770.95M	$1.35	37.36

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	-8.35%	6.87%	2.44%
Royalty Pharma	32.38%	28.21%	14.55%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Royalty Pharma compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

: Corcept Therapeutics currently has a consensus target price of $74.67, suggesting a potential upside of 45.36%. Royalty Pharma has a consensus target price of $50.33, suggesting a potential downside of 0.21%. Given Corcept Therapeutics' higher possible upside, research analysts clearly believe Corcept Therapeutics is more favorable than Royalty Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
1 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.50
Royalty Pharma
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Royalty Pharma has a net margin of 32.38% compared to Corcept Therapeutics' net margin of 6.14%. Royalty Pharma's return on equity of 28.21% beat Corcept Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics 6.14% 7.40% 5.76%
Royalty Pharma 32.38% 28.21% 14.55%
: 93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corcept Therapeutics $761.41M 7.24 $99.65M $0.35 146.76
Royalty Pharma $2.38B 12.24 $770.95M $1.35 37.36
: In the previous week, Corcept Therapeutics had 13 more articles in the media than Royalty Pharma. MarketBeat recorded 25 mentions for Corcept Therapeutics and 12 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.07 beat Corcept Therapeutics' score of 0.01 indicating that Royalty Pharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
Royalty Pharma
8 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Corcept Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Royalty Pharma	32.38%	28.21%	14.55%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	7.24	$99.65M	$0.35	146.76
Royalty Pharma	$2.38B	12.24	$770.95M	$1.35	37.36

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Royalty Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Royalty Pharma beats Corcept Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Royalty Pharma compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

: Nektar Therapeutics currently has a consensus target price of $140.63, suggesting a potential upside of 67.09%. Royalty Pharma has a consensus target price of $50.33, suggesting a potential downside of 0.21%. Given Nektar Therapeutics' higher possible upside, research analysts clearly believe Nektar Therapeutics is more favorable than Royalty Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nektar Therapeutics
1 Sell rating(s)
1 Hold rating(s)

9 Buy rating(s)

0 Strong Buy rating(s)
2.73
Royalty Pharma
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Royalty Pharma has a net margin of 32.38% compared to Nektar Therapeutics' net margin of -297.07%. Royalty Pharma's return on equity of 28.21% beat Nektar Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Nektar Therapeutics -297.07% -380.32% -59.82%
Royalty Pharma 32.38% 28.21% 14.55%
: 75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Royalty Pharma has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nektar Therapeutics $55.23M 51.41 -$164.08M -$10.20 N/A
Royalty Pharma $2.38B 12.24 $770.95M $1.35 37.36
: In the previous week, Nektar Therapeutics had 15 more articles in the media than Royalty Pharma. MarketBeat recorded 27 mentions for Nektar Therapeutics and 12 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.07 beat Nektar Therapeutics' score of 0.10 indicating that Royalty Pharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nektar Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
23 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Royalty Pharma
8 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Nektar Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-297.07%	-380.32%	-59.82%
Royalty Pharma	32.38%	28.21%	14.55%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	51.41	-$164.08M	-$10.20	N/A
Royalty Pharma	$2.38B	12.24	$770.95M	$1.35	37.36

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	23 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Royalty Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Royalty Pharma beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Royalty Pharma compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

: Royalty Pharma has a net margin of 32.38% compared to Supernus Pharmaceuticals' net margin of -5.36%. Royalty Pharma's return on equity of 28.21% beat Supernus Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals -5.36% 12.26% 9.21%
Royalty Pharma 32.38% 28.21% 14.55%
: Supernus Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.
: Royalty Pharma has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Supernus Pharmaceuticals $718.95M 3.97 -$38.55M -$0.68 N/A
Royalty Pharma $2.38B 12.24 $770.95M $1.35 37.36
: In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 12 articles in the media. Royalty Pharma's average media sentiment score of 1.07 beat Supernus Pharmaceuticals' score of 0.75 indicating that Royalty Pharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Royalty Pharma
8 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 54.4% of Royalty Pharma shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Supernus Pharmaceuticals presently has a consensus target price of $62.17, suggesting a potential upside of 26.38%. Royalty Pharma has a consensus target price of $50.33, suggesting a potential downside of 0.21%. Given Supernus Pharmaceuticals' higher possible upside, equities research analysts plainly believe Supernus Pharmaceuticals is more favorable than Royalty Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.43
Royalty Pharma
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-5.36%	12.26%	9.21%
Royalty Pharma	32.38%	28.21%	14.55%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.97	-$38.55M	-$0.68	N/A
Royalty Pharma	$2.38B	12.24	$770.95M	$1.35	37.36

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Royalty Pharma beats Supernus Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RPRX vs. The Competition

Export

Metric	Royalty Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.96B	$3.40B	$6.25B	$11.77B
Dividend Yield	1.87%	2.23%	2.74%	5.26%
P/E Ratio	37.36	38.57	29.25	27.07
Price / Sales	12.24	280.78	504.14	75.42
Price / Cash	10.51	125.06	43.30	53.90
Price / Book	3.00	7.05	9.67	6.69
Net Income	$770.95M	$23.62M	$3.55B	$332.64M
7 Day Performance	1.82%	3.67%	1.70%	2.01%
1 Month Performance	3.85%	7.17%	5.62%	9.19%
1 Year Performance	52.85%	67.04%	34.42%	39.59%

Royalty Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RPRX Royalty Pharma	3.6244 of 5 stars	$50.44 +0.5%	$50.33 -0.2%	N/A	$28.96B	$2.38B	37.36	80	Positive News Upcoming Earnings
ZTS Zoetis	4.9545 of 5 stars	$117.85 +0.8%	$152.25 +29.2%	N/A	$49.16B	$9.47B	19.58	14,500	Positive News Upcoming Earnings Analyst Downgrade
JAZZ Jazz Pharmaceuticals	3.4335 of 5 stars	$201.22 +2.4%	$216.87 +7.8%	N/A	$12.10B	$4.27B	N/A	2,890	News Coverage Positive News Earnings Report
CORT Corcept Therapeutics	4.3702 of 5 stars	$46.22 +0.3%	$77.67 +68.0%	N/A	$4.94B	$761.41M	56.37	300	Earnings Report Analyst Forecast Analyst Revision
NKTR Nektar Therapeutics	2.8775 of 5 stars	$86.74 -5.4%	$140.63 +62.1%	N/A	$3.09B	$55.23M	N/A	220	Trending News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RPRX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Competitors

RPRX vs. ZTS, JAZZ, CORT, NKTR, and SUPN

How does Royalty Pharma compare to Zoetis?

Summary

How does Royalty Pharma compare to Jazz Pharmaceuticals?

Summary

How does Royalty Pharma compare to Corcept Therapeutics?

Summary

How does Royalty Pharma compare to Nektar Therapeutics?

Summary

How does Royalty Pharma compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Royalty Pharma (RPRX) Competitors

RPRX vs. ZTS, JAZZ, CORT, NKTR, and SUPN

How does Royalty Pharma compare to Zoetis?

Summary

How does Royalty Pharma compare to Jazz Pharmaceuticals?

Summary

How does Royalty Pharma compare to Corcept Therapeutics?

Summary

How does Royalty Pharma compare to Nektar Therapeutics?

Summary

How does Royalty Pharma compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools